IAM stock news · Iambic Therapeutics
Get alerts for IAM
Follow Iambic Therapeutics (IAM) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IAMFree on the App Store and Google Play, or on the web.
Iambic Therapeutics shared early research on its drugs IAM-C1 and IAM217 at the ENA 2026 event.
Good for IAMIambic reported tumor activity for IAM-C1 and tumor shrinkage for IAM217 in preclinical models. This is encouraging progress, but neither has shown benefits in patients.
Iambic Therapeutics, Inc. says it finished its first public stock sale and updated its company rules.
NeutralIambic updated its charter and bylaws as its IPO closed and listed ways it may share public information. The filing gives no new business or medicine news, so it does not change the outlook.